|[April 24, 2013]
Research and Markets: Quad 2 (HIV) - Forecast and Market Analysis to 2022
DUBLIN --(Business Wire)--
Research and Markets has announced the addition of the "Quad
2 (HIV) - Forecast and Market Analysis to 2022" report to their
GlobalData has released its new PharmaPoint Drug Evaluation report, Quad
2 (HIV) - Forecast and Market Analysis to 2022. Human Immunodeficiency
Virus (HIV), the causative agent of AIDS, has claimed millions of lives
since its emergence. However, the advent of antiretroviral therapy (ART)
has transformed the face of HIV/AIDS from a deadly disease to a
manageable chronic condition for most infected individuals.
Antiretroviral treatment not only reduces the viral load and
reconstitutes immune function, but also decreases infection incidence
rates by limiting viral transmission. The treatment algorithm in HIV has
characteristically involved multiple drug regimens designed to tackle
the virus on different levels. In the recent past, simplified dosing
regimens through the emergence of single tablet regimens (STRs) or fixed
dose combination (FDC) therapies have become increasingly popular
amongst physicians and patients alike by increasing clinical efficacy
thresholds and enabling atient compliance.
Quad 2 is a single-pill, complete regimen being developed by Gilead for
the treatment of HIV. The drug has a similar formulation to Gilead's
Stribild (elvitegravir/cobicistat/tenofovir disoproxil
fumarate/emtricitabine), except that Quad 2 contains tenofovir
alafenamide fumarate (TAF), which is prodrug of tenofovir disoproxil
fumarate (TDF (News - Alert)).
TAF, previously referred to as GS-7340, requires a 30-fold-less dose to
achieve the same virological effect as TDF (Gilead Sciences, 2012d). The
trend towards physician/patient preference for single-pill, complete
regimen has resulted in Gilead developing TAF exclusively as a component
of a single-tablet regimen, so a standalone formulation of TAF is
unlikely to be pursued.
- Overview of HIV, including epidemiology, etiology, symptoms,
diagnosis, pathology and treatment guidelines as well as an overview on
the competitive landscape.
- Detailed information on Quad 2 including product description, safety
and efficacy profiles as well as a SWOT analysis.
- Sales forecast for Quad 2 for the top nine countries from 2012 to 2022.
- Sales information covered for the US, France, Germany, Italy, Spain,
the UK, Japan, Brazil and China
Reasons to buy
- Understand and capitalize by identifying products that are most likely
to ensure a robust return
- Stay ahead of the competition by understanding the changing
competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying
drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth
analysis of Quad 2 performance
- Obtain sales forecast for Quad 2 from 2012-2022 in top nine countries
(the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China)
For more information visit Research
About Research and Markets
Research and Markets is the world's leading source for international
market research reports and market data. We provide you with the latest
data on international and regional markets, key industries, the top
companies, new products and the latest trends.
[ InfoTech Spotlight's Homepage ]